BIO vs. BMRN: Bio-Rad Laboratories vs. BioMarin Pharmaceutical Stock Comparison
How do Bio-Rad Laboratories (BIO) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and BioMarin Pharmaceutical (BMRN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while BMRN is classified in Biotechnology.
| Profile Item | BIO | BMRN |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.26 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Total Return (1Y) | 28.31% | 8.82% |
| Total Return (3Y, Annualized) | 8.52% | -12.54% |
| Total Return (5Y, Annualized) | -11.74% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 35.50% |
| Beta (5Y) | 1.03 | 0.24 |
| Max Drawdown (5Y) | -72.24% | -57.64% |
| Avg. Volume (3M) | 250.78K | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 0.13 |
| Sortino Ratio (1Y) | 0.98 | 0.23 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO) reports 14.27%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Bio-Rad Laboratories (BIO) reports 39.45%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | BMRN |
|---|---|---|
| ROE (TTM) | 14.27% | -0.31% |
| ROA (TTM) | 1.50% | 3.89% |
| Net Margin (TTM) | 39.45% | -0.52% |
| Operating Margin (TTM) | 11.82% | 26.58% |
| Gross Margin (TTM) | 52.19% | 53.21% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 12.87% |
| Revenue Growth (3Y CAGR) | -2.68% | 15.40% |
| EPS Growth (YoY) | -- | -18.55% |
| EPS Growth (3Y CAGR) | -- | 33.89% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.44 |
| Debt / Equity (MRQ) | 0.18 | 0.67 |
| Net Debt / EBITDA | -0.73 | 4.04 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO) trades at 10.14 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while BioMarin Pharmaceutical (BMRN) at 1.73 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | -- |
| P/S Ratio (TTM) | 3.96 | 2.97 |
| P/B Ratio (MRQ) | 1.35 | 1.73 |
| Free Cash Flow Yield (TTM) | 2.65% | -0.15% |